Trials / Completed
CompletedNCT00858208
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Long-Term Non-Interventional Study To Investigate The Efficacy And Safety Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 86 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
Detailed description
Eligible patients in routine clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium | pegaptanib sodium intravitreal injection every 6 weeks for 2 years |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2009-03-09
- Last updated
- 2012-04-11
- Results posted
- 2012-04-11
Locations
8 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00858208. Inclusion in this directory is not an endorsement.